A 24-week, multicenter, randomized, open-label, parallel group clinical study to compare the efficacy and safety of oral quadruple hypoglycemic agents including SGLT2 inhibitor and triple hypoglycemic agents including GLP-1 receptor agonist in patients with type 2 diabetes mellitus, uncontrolled with oral triple hypoglycemic agents
Latest Information Update: 31 Mar 2026
At a glance
- Drugs Empagliflozin (Primary) ; Dulaglutide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
Most Recent Events
- 31 Mar 2026 New trial record